Here are the 10-K annual reports from Sight Sciences, Inc. (SGHT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SGHT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGHT filings page.
Sight Sciences, Inc. is an eyecare technology company focused on interventional treatments for glaucoma and dry eye disease. It develops devices designed to restore the eye’s natural drainage and tear-film function, targeting large but under-served markets.
The company’s interventional glaucoma business centers on the OMNI Surgical System and the SION Surgical Instrument, which enable minimally invasive glaucoma surgery in both cataract-combination and standalone procedures. For dry eye, its TearCare system delivers controlled heat and manual gland expression to treat meibomian gland disease, supported by randomized clinical trials such as OLYMPIA and SAHARA and health-economic studies showing potential cost savings versus prescription drops.
Sight Sciences emphasizes clinical evidence, reimbursement access, and specialized sales teams in the U.S. and select international markets. As of June 30, 2025, non-affiliate market value was about $153.6 million, and 54,005,984 common shares were outstanding as of February 26, 2026.